Form 4: Clover Health CEO Sells Shares Under 10b5-1 Plan

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, reported a planned sale of 5,833 shares of Class A Common Stock for a weighted average price of $1.91 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., reported a planned sale of company stock.
• The transaction involves the disposition of 5,833 shares of Class A Common Stock.
• The shares are scheduled to be sold on March 18, 2026, at a weighted average price of $1.91 per share.
• The sale is executed under a Rule 10b5-1 trading plan, which was adopted by Reynoso on March 13, 2025.
• Following this transaction, Reynoso will beneficially own 2,716,735 shares of Class A Common Stock.
• The shares are planned to be sold in multiple transactions within a price range of $1.87 to $1.96.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because it is a routine insider transaction executed under a pre-established 10b5-1 plan, rather than a discretionary sale based on new information.

Positives

• The sale is conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an immediate reaction to new, non-public information, which is a standard practice for corporate insiders.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.
• The planned sale price of $1.91 is relatively low, potentially reflecting current market valuation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even pre-planned, are common for executive compensation and diversification. The specific impact on Clover Health depends on the broader market sentiment towards healthcare technology and Medicare Advantage plans, which are currently experiencing significant regulatory and competitive pressures.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are standard practice across publicly traded companies for executives to manage their equity holdings and diversify personal portfolios while adhering to insider trading regulations. For example, similar planned sales are routinely seen at companies like UnitedHealth Group (UNH) or Humana (HUM) by their executives.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally viewed as routine when under a 10b5-1 plan, indicating no immediate change in company fundamentals.

Key Dates

Recommendation

The filing reports a routine insider sale under a pre-established 10b5-1 plan, which is not indicative of new fundamental information about Clover Health. Therefore, it does not warrant a change in investment recommendation based solely on this transaction. Investors should hold their positions and consider broader company performance and market trends.

Keywords

Clover Health, CLOV, Insider Sale, Form 4, Jamie L. Reynoso, 10b5-1 Plan, Stock Transaction, CEO, Medicare Advantage